Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

CD117 expression in glial tumors.

Neslihan Cetin1, Gerald Dienel, Murat Gokden

  • 1Department of Pathology, University of Arkansas for Medical Sciences, 4301 W. Markham St., Little Rock, AR 72205, USA.

Journal of Neuro-Oncology
|September 1, 2005
PubMed
Summary

CD117 expression is common in brain tumors, particularly high-grade gliomas. This finding suggests CD117 may drive tumor growth and could be a target for new brain tumor treatments.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Spinal neurosarcoidosis mimicking intramedullary tumors without systemic symptoms: Report of two cases and a systematic review.

Surgical neurology international·2026
Same author

Can Transcutaneous Vagus Nerve Stimulation be Effective After Rats' Spinal Cord Injury?

Cureus·2026
Same author

Illuminating Blurry Vision: Visualization of Corneal Protein Deposition With Immunofluorescence in Two Illustrative Case Reports.

Case reports in pathology·2026
Same author

Pathologic Variability Associated With Phenotypic Differences in Siblings With ACTA1 Myopathy.

Muscle & nerve·2026
Same author

Intracranial mesenchymal tumor, FET::CREB fusion-positive: An integrative analysis of 81 cases.

Neuro-oncology·2026
Same author

Targeted Inhibition in Pediatric MET and ALK-Altered Hemispheric Gliomas: Objective Responses Followed by Treatment Resistance.

International journal of molecular sciences·2025

Area of Science:

  • Neuro-oncology
  • Molecular pathology
  • Cancer biology

Background:

  • C-kit (CD117) is a proto-oncogene crucial in development and cancer.
  • CD117 is a specific marker for gastrointestinal stromal tumors (GISTs).
  • GISTs expressing CD117 respond well to tyrosine kinase inhibitors, suggesting therapeutic potential.

Purpose of the Study:

  • To investigate CD117 expression in central nervous system (CNS) tumors.
  • To determine if CD117 expression correlates with tumor grade or type.
  • To explore potential therapeutic implications of CD117 in brain tumors.

Main Methods:

  • Immunohistochemical assay for CD117 expression.
  • Analysis of 52 glial tumor specimens of diverse histologic types and grades.
  • Statistical comparison of CD117 immunoreactivity across tumor grades.

Main Results:

  • CD117 immunoreactivity was detected in approximately 75% of glial tumors.
  • Strong cytoplasmic and membranous staining was observed in most positive cases.
  • High-grade tumors, including glioblastoma and anaplastic oligodendroglioma, showed significantly higher CD117 expression than low-grade tumors.

Conclusions:

  • CD117 is frequently expressed in glial tumors, especially high-grade types.
  • CD117 may play a role in the growth of brain tumors.
  • Targeting CD117 with receptor tyrosine kinase inhibitors could offer new therapeutic strategies for brain tumor patients.

Related Experiment Videos